

VioQuest Pharmaceuticals, Inc.  
Form 8-K  
September 11, 2008

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

**FORM 8-K**

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): September 10, 2008

**VioQuest Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation)

**000-16686**  
(Commission File Number)

**58-1486040**  
(IRS Employer  
Identification No.)

**180 Mt. Airy Road, Suite 102**  
**Basking Ridge, NJ 07920**  
(Address of principal executive offices)

**(908) 766-4400**  
(Registrant's telephone number, including area code)

**N/A**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



**Item 8.01**

**Other Events.**

On September 9, 2008, VioQuest Pharmaceuticals, Inc. (the “Company”) received a determination from the U.S. Food and Drug Administration that Xyfid™ (1% uracil topical) is a drug rather than a device and would be regulated with the Center for Drug Evaluation and Research as opposed to the Center for Devices and Radiologic Health. Thus, Xyfid is not eligible for marketing clearance pursuant to the 510(k) process, but the Company will continue its parallel development of Xyfid for the prevention of hand-foot syndrome.

On September 10, 2008, the Company released the press release filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and the press release is incorporated herein by reference.

**Item 9.01**

**Financial Statements and Exhibits.**

(d) *Exhibits*

	<u>Exhibit No.</u>	<u>Description</u>
	99.1	Press release of the Company dated September 10, 2008.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**VioQuest Pharmaceuticals, Inc.**

Date: September 11, 2008

By:

/s/ Christopher P. Schnittker

Christopher P. Schnittker  
Vice President & Chief Financial Officer